Asking the quintessential Australian question at #EULAR24 by @drdavidliew - does the ORAL surveillance study for JAKi *truly* pass the pub test? @eular_org @Janetbirdope @RheumNow What does #MedTwitter think? https://t.co/bqwPU8XX5S

• https://twitter.com/benjaminsutu/status/1800875690486792649/photo/1
• https://twitter.com/benjaminsutu/status/1800875690486792649/photo/1
• https://twitter.com/benjaminsutu/status/1800875690486792649/photo/1

Pt with LN, endocarditis, pericarditis, arthritis, rash failed CTX, MMF, BEL, and SOC. She is 1000 days post CAR-T cell. Off immunomodulating drugs. #SLE in remission clinically and serologically. - Dr G Schett #EULAR24 @RheumNow https://t.co/3vdMtO6VWI

• https://twitter.com/KDAO2011/status/1800873281085710534/photo/1

#EULAR2024 JAK-i Debate. @Janetbirdope [Pro Regulatory Safety Measures] - to do no harm esp since there are other alternatives - supported by RCT - although JAK-i have different structures, data from individual RCT + LTE showed similar rates of malignancy & MACE @RheumNow https://t.co/jQKQmHE9Fg

• https://twitter.com/Yuz6Yusof/status/1800871776114860105/photo/1
• https://twitter.com/Yuz6Yusof/status/1800871776114860105/photo/1

Areas to consider in difficult to manage PsA and research agenda #EULAR2024 Chandran V @RheumNow https://t.co/sp4tkAivLa

• https://twitter.com/synovialjoints/status/1800871763460636944/photo/1
• https://twitter.com/synovialjoints/status/1800871763460636944/photo/1

Significant proportion of patients in PsA do not achieve remission across the domains. This can be due to disease heterogeneity, domain differences, comorbidities. There is a need to study the use of combination ts and bDMARDs. Difficult to Manage PsA session #EULAR2024 Ribeiro,… https://t.co/Wt3jgtIR9N https://t.co/VzCApikqek

• https://twitter.com/i/web/status/1800870035440775350
• https://twitter.com/synovialjoints/status/1800870035440775350/photo/1
• https://twitter.com/synovialjoints/status/1800870035440775350/photo/1

Join us later for a some very exciting pieces of translational science across a AIRDs. All these abstracts sharing one thing in common: tissue, tissue, tissue! 16:30-18:00 Room A8.2 @RheumNow #EULAR2024 https://t.co/HrHP5tmHDD

• https://twitter.com/AurelieRheumo/status/1800868919684829560/photo/1

Grappa - distinguish D2T from complex to manage - objective signs of inflammation imaging - US or MRI not lab markers @rheumnow #EULAR2024

#EULAR2024 Eular Debate Showdown between @Janetbirdope vs @drdavidliew Topic: can observational study debunk RCT? This stemmed from Oral Surveillance = an increased risk of malignany & MACE with tofacitinib compared with TNF-i. Regulatories extrapolated to all JAK-i @RheumNow https://t.co/hg6xJZDHiA

• https://twitter.com/Yuz6Yusof/status/1800867028850577678/photo/1

The great debate on JAKi risk and special warnings And who better than @RheumNow to keep score between @Janetbirdope & @drdavidliew Get the popcorn ready 🍿 #EULAR2024 https://t.co/z50Ob8q0i0

• https://twitter.com/AurelieRheumo/status/1800866706077958184/photo/1

almost half PsA patients have 3 pr more co-morbidities and 67% of those surveyed do not think rheumos should not manage them - when did we stop being physicians ? @rheumnow #EULAR2024

« difficult to treat PsA » how mich combination obesity, non-inflammatory MSK pain, fibromyalgia and depression making assessment tricky and risk of rattling through therapies fast! @rheumnow #EULAR2024

Dr. D Aletaha defines The #EULARManifesto, "It is about patient centeredness-- improving quality of care, advocating for patients, timely access to specialists, pushing R&D innovation, integrating technology to make sure every patient gets the care they need." @rheumnow #EULAR24

🌎 Global disparities in steroid prescribing in #SLE 💊 HCQ assoc with decreased steroid use 📈 Other contributing factors may be prevalence, severity & phenotype of disease, plus access to DMARDs & biologics 📍SLE poster tour 15:30 TODAY #EULAR2024 Abs #POS0013 @RheumNow https://t.co/7pL8kpeqOs

• https://twitter.com/DrMiniDey/status/1800833564180963574/photo/1

LBA0001 (2024) EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH GIANT CELL ARTERITIS (SELECT-GCA): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL - looking good, nice results @rheumnow #EULAR2024

LONG-TERM EFFICACY TOCILIZUMAB AFTER ULTRA-SHORT GC TO TREAT GCA: 3 Yr FOLLOW-UP OF THE GUSTO TRIAL 3 day GC pulse immediate 12 mths Toci 85% drug free remission at 4 yrs! @rheumnow #EULAR2024